Coherus BioSciences Revenue and Competitors
Estimated Revenue & Valuation
- Coherus BioSciences's estimated annual revenue is currently $22.8M per year.
- Coherus BioSciences received $75.0M in venture funding in January 2019.
- Coherus BioSciences's estimated revenue per employee is $52,743
- Coherus BioSciences's total funding is $477.5M.
- Coherus BioSciences has 432 Employees.
- Coherus BioSciences grew their employee count by 15% last year.
What Is Coherus BioSciences?
Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit www.coherus.com. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power
Number of Employees
Employee Growth %
Coherus BioSciences News
... chief medical officer of Coherus BioSciences in Redwood City, CA. ... the leadership team of Coherus with his deep clinical development...
Coherus BioSciences, Inc. (NASDAQ:CHRS) Expected to Announce Quarterly Sales of $71.08 Million. Posted by admin on Apr 27th, 2022.
Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Rating of Buy by Brokerages. Posted by admin on Apr 26th, 2022.
BidaskClub cut shares of Coherus Biosciences (NASDAQ:CHRS) from a buy rating to a hold rating in a report released on Friday, BidAskClub ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Coherus BioSciences Funding
|2014-11-07||$85.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2015-03-31||$115.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2015-04-02||$138.0M||Undisclosed||J.P. Morgan Securities LLC||Article|
|2019-01-08||$75.0M||Undisclosed||Healthcare Royalty Partners||Article|